A STUDY TO EVALUATE THE EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR AND RENAL OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT A TERTIARY CARE HOSPITAL, IN TELANGANA

K. VASANTHA KUMARI; MEHER KOUNEN FATIMA; FARHEEN SULTANA; CHAKRADHAR T.; MOHD MOOSA QUADRI

doi:10.22159/ijpps.2025v17i3.53190

Authors

K. VASANTHA KUMARI Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India
MEHER KOUNEN FATIMA Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India
FARHEEN SULTANA Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India https://orcid.org/0009-0004-6818-0893
CHAKRADHAR T. Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India https://orcid.org/0009-0000-7208-001X
MOHD MOOSA QUADRI Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India

DOI:

https://doi.org/10.22159/ijpps.2025v17i3.53190

Keywords:

Type 2 diabetes mellitus, Metformin, Empagliflozin, Cardiovascular outcomes, Renal outcomes

Abstract

Objective: The objective of this study is to evaluate the effects of Empagliflozin on cardiovascular and renal outcomes in Type 2 Diabetes Mellites (T2DM) patients, particularly focusing on improvements in glycemic control, weight, blood pressure, and renal function after 6 months of treatment.

Methods: A cross-sectional observational study was conducted at Osmania Medical College and Hospitals, Hyderabad over six months, involving 120 patients with T2DM. The patients were randomly divided into two groups. Group 1 patients received standard Oral Hypoglycemic Agents (OHAs) such as Metformin. Group 2 patients received the same OHAs along with Empagliflozin 10 mg. Baseline and post-treatment data for key parameters such as blood glucose levels, blood pressure, Body Mass Index (BMI), and renal function markers (e.g., serum creatinine) were collected. The t-test was used for statistical analysis to compare pre-and post-treatment values.

Results: After six months of treatment, the following significant improvements were observed in the group receiving Empagliflozin: Diastolic blood pressure: A significant reduction of 7 mmHg (p = 0.00066), BMI: A reduction of 1.6 units (p = 0.0107), Key glycemic parameters showed significant improvements: Fasting Blood Sugar (FBS): p = 0.000212, Random Blood Sugar (RBS): p < 0.00001, HbA1c levels: p = 0.000147. These results indicate that Empagliflozin significantly improved glycemic control, blood pressure, and weight, which are all key factors contributing to improved cardiovascular and renal health in T2DM patients.

Conclusion: The addition of Empagliflozin to standard T2DM treatment resulted in significant improvements in glycemic control, body weight, and blood pressure, particularly diastolic blood pressure, over the 6-month study period. These changes are likely to contribute to improved cardiovascular and renal outcomes in patients with T2DM. Thus, Empagliflozin offers a valuable therapeutic option for enhancing overall disease management in T2DM patients with complications.

Downloads

Download data is not yet available.

References

World Health Organisation. The top 10 causes of death. http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death

Rajendra Pradeepa, Vishwanath Mohan. Epidemiology of Type 2 Diabetes in India.

Indian Journal of Ophthalmology. 2021; Vol 69(11): 2932-2938.

Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, Joshi S, Bajaj S, Jabbar PK, Das HK, Kumar A, Dhandhania VK, Bhansali A, Rao PV, Desai A, Kalra S, Gupta A, Lakshmy R, Madhu SV, Elangovan N, Chowdhury S, Venkatesan U, Subashini R, Kaur T, Dhaliwal RS, Mohan V; ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023 Jul;11(7):474-489.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 ;38(1):140-149.

Ramanathan, Balamurugan, Duraisamy, Ramesh, Venkatramanasami, Balaji Tulse Dass, Abbas, Manoj Kumar and Balamurugan, Aswinram. "Association of glycaemic status and outcomes in diabetic foot problems: a retrospective evidence from South India. Journal of Basic and Clinical Physiology and Pharmacology. 2022; 33(2): 155-162.

Ismail L, Materwala H, Al Kaabi J. Association of risk factors with type 2 diabetes: A systematic review. Comput Struct Biotechnol J. 2021 Mar 10;19: 1759-1785.

Jasvinder Singh Bhatti, Abhishek Sehrawat, Jayapriya Mishra, Inderpal Singh Sidhu, Umashanker Navik, Naina Khullar, Shashank Kumar, Gurjit Kaur Bhatti, P. Hemachandra Reddy. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: Current therapeutics strategies and future perspectives. Free Radical Biology and Medicine.2022; 184:114-134.

Batista, T.M., Haider, N. & Kahn, C.R. Defining the underlying defect in insulin action in type 2 diabetes. Diabetologia. 2021; 64:994–1006.

Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P. SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. 2022; 183:106396.

Triplitt CL, Reasner CA, II, Isley WL. Diabetes mellitus. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, New York: McGraw-Hill; 2008. pp. 1205–1241.

Frampton JE. Empagliflozin: A Review in Type 2 Diabetes. Drugs. 2018 Jul;78(10):1037-1048.

Paczkowska A, Hoffmann K, Michalak M, Bryl W, Kopciuch D, Zaprutko T, Ratajczak P, Nowakowska E, Kus K. A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up. Diabetes Metab Syndr Obes. 2021 Jul 14;14: 3243-3252.

Anker SD, Usman MS, Butler J. SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy. Circulation. 2022 Jul 26;146(4):299-302. doi: 10.1161/CIRCULATIONAHA.122.060348. Epub 2022 Jul 25.

Ndefo UA, Anidiobi NO, Basheer E, Eaton AT. Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes. P T. 2015 Jun;40(6):364-8.

Inzucchi SE, Davies MJ, Khunti K, Trivedi P, George JT, Zwiener I, Johansen OE, Sattar N. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. Diabetes ObesMetab. 2021 Feb;23(2):425-433.

Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol. 2021 Feb 10;83: 503-528.

Min S.H., Yoon J.H., Hahn S., Cho Y.M. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: A systematic review with indirect comparison meta-analysis. Diabetes Metab. Res. Rev. 2017;33: e2818.

Chacko J, Dhandapani S, Jahagiridhar V, Swaminathan K. The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: A short-term observational study. Indian J Pharmacol. 2021 May-Jun;53(3):229-233.

Baker WL, Smyth LR, Riche DM. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262–275.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.

Takata T,Isomoto H. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control. Int J Mol Sci. 2021 Apr 22;22(9):437.